logo-loader
RNS
AstraZeneca PLC

AstraZeneca PLC - Chair succession

RNS Number : 1646U
AstraZeneca PLC
29 July 2022
 

29 July 2022 07:01 BST

 

 

Michel Demaré to succeed Leif Johansson as

Non-Executive Chair of the Board

 

AstraZeneca PLC today announced the appointment of Michel Demaré as the Chair-designate of the Board.

 

His appointment followed a robust succession planning process led by Philip Broadley in his capacity as senior independent Non-Executive Director.

 

As previously communicated, Leif Johansson, current Chair of the Board of AstraZeneca will be retiring at the conclusion of the Company's Annual General Meeting in April 2023.  Michel's appointment will take effect immediately on Leif's retirement allowing for a managed handover period over the coming months.

 

Michel was appointed to the Board of AstraZeneca in September 2019 as an independent Non-Executive Director and is currently Chair of the Company's Remuneration Committee and member of the Audit Committee and the Nomination and Governance Committee.  He is a Non-Executive Director of Vodafone Group Plc and Louis Dreyfus Int'l Holdings BV.  He is also Chairman of IMD Business School and Chairman of Nomoko AG.

 

Leif Johansson, AstraZeneca Chair said: "I am delighted that Michel will succeed me following the 2023 AGM.  He is an internationally respected leader with extensive experience in strategy, planning, execution, governance and corporate stewardship and a proven track record leading multinational companies, as well as experience of the pharmaceutical industry gained at Baxter and as a member of the AstraZeneca Board.  I look forward to undertaking a comprehensive handover in the coming months and to seeing the continued development and success of AstraZeneca."

 

Michel Demaré, AstraZeneca Chair-designate said: "I could not be prouder to be named Chair-designate of the Board of AstraZeneca and am excited to have the opportunity to build on Leif's success as Chair and work with Pascal and members of the Board and Senior Executive Team when I take on my new role in 2023."

 

Notes

 

Biography and photograph:

https://www.astrazeneca.com/our-company/leadership.html#board

 

Remuneration:

Effective 1 May 2023, the fee for the Chair of the Board will be £800,000 per annum, paid wholly in cash.  The Chair's fee was last increased in January 2018.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAUWUBRURUBUAR
NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.

It is important for you to know that:

(a) none of the Content is, or is intended to be, general or personal advice

(b) the principal purpose of the Content is to provide factual information only and to comment on news;

(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;

(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and

(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.

The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.

In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read